Drug intelligence / Profile preview

bevacizumab + carboplatin + cisplatin + pemetrexed

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This is a combination of four drugs used in cancer treatment. Bevacizumab is an anti-angiogenic monoclonal antibody that targets vascular endothelial growth factor (VEGF). Carboplatin and cisplatin are platinum-based chemotherapy agents. Pemetrexed is a multi-targeted anti-folate agent. In clinical practice, bevacizumab is typically combined with either carboplatin/pemetrexed or cisplatin/pemetrexed, but not with both platinum agents simultaneously.

Targets

DNATS (Thymidylate synthase)DHFR (Dihydrofolate reductase)VEGFA (Vascular endothelial growth factor A)GART (GAR transformylase)

Beyond the preview

Go deeper on bevacizumab + carboplatin + cisplatin + pemetrexed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + carboplatin + cisplatin + pemetrexed.

Explore the full profile